St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr
- Address
- lock Available on a paid plan
Immune-Mediated Rheumatology Research
At St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr, the Rheumazentrum Ruhrgebiet is conducting clinical research focused on immune system diseases and related immune system processes. The studies center on inflammatory conditions that affect daily function and quality of life, with an emphasis on understanding how new treatments may support long-term disease control.
- Psoriatic arthritis and treatment effectiveness
- Sjögren’s syndrome and long-term safety
- Active idiopathic inflammatory myopathy and symptom management
The research activity here is aimed at evaluating whether newer therapies can provide lasting benefit while remaining safe and well tolerated for people living with chronic inflammatory rheumatic disease.
Musculoskeletal Inflammation and Autoimmune Disease Studies
This site also contributes to research in musculoskeletal diseases and musculoskeletal and neural physiological phenomena, reflecting a strong focus on disorders that involve pain, stiffness, weakness, and impaired movement. The clinical trials are designed to better understand how targeted therapies may improve disease activity in autoimmune conditions affecting muscles and joints.
- Polymyositis and dermatomyositis
- Idiopathic inflammatory myopathy
- Functional impact of inflammatory muscle disease
These studies are exploring new treatment options and assessing whether they can improve outcomes for patients with complex inflammatory muscle disorders.
Connective Tissue and Skin-Related Inflammatory Research
Clinical trials at this hospital-based research site also extend into skin and connective tissue diseases, where autoimmune inflammation can affect both internal organs and visible tissues. The work supports a broader effort to test therapies that may reduce disease activity and offer more durable control of chronic immune-related illness.
- Sjögren’s syndrome as a connective tissue disease
- Dermatomyositis with skin involvement
- Inflammation affecting connective tissue and glands
Overall, the research program is centered on improving treatment effectiveness, confirming long-term tolerability, and advancing care for patients with autoimmune conditions seen in rheumatology practice.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 126 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 122 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 26 by active trials.
- 1Merck Sharp & Dohme LLC5active
lock +25 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG9trials
lock +15 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr
lock Showing 1 of 76 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 126 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ianalumab | 6 | Unknown | 2022-07-14 | 2024-11-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.